NEWS
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various CNS diseases, including Alzheimer's Disease, where myelin loss compromises neuron function. The company expects to report top-line cognitive results from its Phase II Early AD patients trial in first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
103773561 : should i stay?or it y again?
Jaguar8 OP 103773561 : I don’t give such advice
103773561 : but is it will pump again?
Jaguar8 OP 103773561 : We will never know